COVID-19 is turning out to be like the board game snakes and ladders, with the drugs seen as potential treatments being the players and clinical trials the snakes.
Is Dexamethasone The Next Hydroxychloroquine For India?
Zydus Cadila, Wockhardt, Cadila And Cipla Could Gain
While the jury is still out on dexamethasone being the new hero in the fight against COVID-19 after the hype around hydroxychloroquine has died down, Indian pharma is watching developments closely. Gains of companies like Zydus Cadila, Wockhardt, Cadila and Cipla in the domestic market will be constrained by price caps while any increase in exports will depend on emergency use authorizations.
